

Estela Giménez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030930/publications.pdf>

Version: 2024-02-01

73
papers

1,045
citations

430874

18
h-index

552781

26
g-index

73
all docs

73
docs citations

73
times ranked

1470
citing authors

#	ARTICLE	IF	CITATIONS
1	Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	3
2	Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2021, 93, 5167-5172.	5.0	8
3	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. <i>American Journal of Transplantation</i> , 2021, 21, 258-271.	4.7	11
4	Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera. <i>Journal of Medical Virology</i> , 2021, 93, 2301-2306.	5.0	12
5	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. <i>Bone Marrow Transplantation</i> , 2021, 56, 1281-1290.	2.4	3
6	SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19.. <i>Transplantation</i> , 2021, Publish Ahead of Print, 1372-1380.	1.0	17
7	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
8	Performance of a MALDI-TOF mass spectrometry-based method for rapid detection of third-generation oxymino-cephalosporin-resistant <i>Escherichia coli</i> and <i>Klebsiella</i> spp. from blood cultures. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1925-1932.	2.9	7
9	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021, 23, e13627.	1.7	5
10	T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 2785-2794.	4.7	17
11	Cytomegalovirus-specific T cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. <i>British Journal of Haematology</i> , 2021, 195, 637-641.	2.5	4
12	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 431-440.	2.4	13
13	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	4.8	8
14	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , 2020, 22, e13206.	1.7	13
15	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	3.3	2
16	Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13240.	1.7	16
17	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	1.7	7
18	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	1.7	7
20	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1347-1356.	2.4	9
21	A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. <i>Journal of Infectious Diseases</i> , 2020, 222, 479-487.	4.0	2
22	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
23	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
24	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019, 54, 90-98.	2.4	12
25	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	1.7	17
26	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	4.7	45
27	Cytomegalovirus DNAemia in patients with <i>de novo</i> acute myeloid leukemia undergoing cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3081-3083.	1.3	0
28	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	4.8	3
29	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. <i>Medical Microbiology and Immunology</i> , 2019, 208, 253-258.	4.8	19
30	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	3.3	17
31	Spontaneously resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019, 91, 1128-1135.	5.0	3
32	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	5.8	36
33	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1510-1512.	4.0	2
34	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 22-27.	1.8	5
35	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
36	Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1139-1149.	4.7	57

#	ARTICLE	IF	CITATIONS
37	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018, 53, 787-790.	2.4	5
38	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018, 90, 1375-1382.	5.0	3
39	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2885-2894.	4.7	22
40	Are pathogenic intestinal bacteria present in stool specimens from patients with chronic heart failure?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 141-143.	1.8	5
41	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , 2018, 67, 805-807.	5.8	12
42	Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	9
43	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 563-570.	2.0	31
44	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2331-2339.	2.9	7
45	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	1.7	24
46	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
47	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	1.8	2
48	Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12717.	1.7	18
49	Comparison of the artus Epstein-Barr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 36-38.	1.8	12
50	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. <i>Transplant Infectious Disease</i> , 2017, 19, e12773.	1.7	26
51	Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Clinical Virology</i> , 2017, 94, 22-28.	3.1	44
52	Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?. <i>Journal of Clinical Virology</i> , 2017, 97, 26-32.	3.1	9
53	IL28B genetic variation and cytomegalovirus-specific T cell immunity in allogeneic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2017, 89, 685-695.	5.0	10
54	Assessing the risk of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma. <i>Journal of General Virology</i> , 2017, 98, 1855-1863.	2.9	2

#	ARTICLE	IF	CITATIONS
55	The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of General Virology</i> , 2017, 98, 2530-2542.	2.9	10
56	Short-term incubation of positive blood cultures in brain-heart infusion broth accelerates identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry. <i>Journal of Medical Microbiology</i> , 2017, 66, 1752-1758.	1.8	15
57	Would Kinetic Analyses of Plasma Cytomegalovirus DNA Load Help to Reach Consensus Criteria for Triggering the Initiation of Preemptive Antiviral Therapy in Transplant Recipients?: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 1533-1535.	5.8	9
58	Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. <i>Transplant International</i> , 2016, 29, 1196-1204.	1.6	4
59	Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw107.	0.9	36
60	Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. <i>Journal of General Virology</i> , 2015, 96, 2822-2831.	2.9	29
61	Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 40-43.	1.8	21
62	Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCPâ€1, ILâ€10, and TLR9 genes. <i>Journal of Medical Virology</i> , 2015, 87, 248-255.	5.0	19
63	An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. <i>Future Virology</i> , 2015, 10, 113-134.	1.8	33
64	Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. <i>Journal of Medical Virology</i> , 2015, 87, 1601-1607.	5.0	5
65	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2741-2744.	3.9	15
66	Plasma metabolomics profiling for the prediction of cytomegalovirus DNAemia and analysis of virusâ€host interaction in allogeneic stem cell transplant recipients. <i>Journal of General Virology</i> , 2015, 96, 3373-3381.	2.9	6
67	Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 ⁺ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5602-5605.	3.2	24
68	Early Kinetics of Plasma Cytomegalovirus DNA Load in Allogeneic Stem Cell Transplant Recipients in the Era of Highly Sensitive Real-Time PCR Assays: Does It Have Any Clinical Value?. <i>Journal of Clinical Microbiology</i> , 2014, 52, 654-656.	3.9	31
69	An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting. <i>Journal of Medical Virology</i> , 2014, 86, 568-575.	5.0	19
70	Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. <i>Journal of Medical Virology</i> , 2014, 86, 838-844.	5.0	39
71	Active cytomegalovirus infection is not a risk factor for <scp>E</scp>psteinâ€ <scp>B</scp>arr virus <scp>DNA</scp>emia in the allogeneic stem cell transplantation setting. <i>Clinical Transplantation</i> , 2014, 28, 508-511.	1.6	0
72	Evaluation of the Architect Epstein-Barr Virus (EBV) Viral Capsid Antigen (VCA) IgG, VCA IgM, and EBV Nuclear Antigen 1 IgG Chemiluminescent Immunoassays for Detection of EBV Antibodies and Categorization of EBV Infection Status Using Immunofluorescence Assays as the Reference Method. <i>Vaccine Journal</i> , 2014, 21, 684-688.	3.1	19

#	ARTICLE	IF	CITATIONS
73	Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 207-209.	1.8	43